Professional Documents
Culture Documents
Abstract
Introduction
Achalasia is a rare primary esophageal motor disorder
characterized by the absence of peristalsis and a defective
relaxation of the lower esophageal sphincter (LES)
resulting in impaired bolus transport and food stasis in the
esophagus [1]. Achalasia occurs equally in men and women
with an incidence of 1 in 100,000 individuals and a prevalence
of 10 in 100,000. The peak incidence occurs between 30 and
60years of age [2,3]. The most frequent symptoms of achalasia
are dysphagia for both solids and liquids, regurgitation
of saliva and undigested food, respiratory complications
(nocturnal cough and aspiration), chest pain, heartburn,
Department of Medical and Surgical Sciences, Gastroenterology and
Endoscopy Unit, Policlinico Sant Orsola-Malpighi, University of
Bologna, Bologna, Italy
Conflict of Interest: None
Correspondence to: Francesco Torresan, Department of Medical and
Surgical Sciences, Gastroenterology and Endoscopy Unit, Policlinico
Sant Orsola-Malpighi, University of Bologna, Via Massarenti 9,
40138Bologna, Italy, Tel.: +39051 6364358,
e-mail: francesco.torresan@aosp.bo.it
Received 17October 2014; accepted 21November 2014
2015 Hellenic Society of Gastroenterology
302 F. Torresan et al
Dysphagia
Regurgitation
Retrosternal
pain
Weight
loss (kg)
None
None
None
Occasional
Occasional
Occasional
Daily
Daily
Daily
5-10
Each meal
Each meal
Each meal
>10
None
Type II
Type III
<5
Treatment of achalasia
Pharmacological therapy
B
Type I
High IRP
Absent peristalsis
Absent contractile activity
Type II
Normal IRP
Absent peristalsis
Absent contractile activity
Resolution of pressurization
Type III
High IRP
Absent peristalsis
2 or more spastic contractions with or without
periods of compartmentalized pressurization
1
5
150
10
100
15
20
50
25
30
30
0
35
Time (s)
Time (s)
Time (s)
Figure 1 Achalasia subtypes according to Chicago classification. (A) Type I (classic achalasia) refers to patients with absence of peristalsis, no
pressurization within the esophageal body, high integrated relaxation pressure (IRP). (B) Type II (achalasia with compression) refers to patients
with absence of peristalsis, and contractile activity, panesophageal pressurization >30 mmHg, and high IRP. (C) Type III patient (spastic achalasia),
refers to patients with absence of peristalsis, and two or more spastic contractions with or without periods of compartmentalized pressurization
and a high IRP
PD
304 F. Torresan et al
LHM
PD versus LHM
POEM
Other therapies
Self-expanding metallic stents
Endoscopic sclerotherapy
Future therapies
306 F. Torresan et al
Concluding remarks
The recent emergence of the HRM as a diagnostic tool has helped
identify three subtypes of achalasia that show different responsiveness
to endoscopic or surgical therapies. This subclassification has
facilitated choosing the appropriate treatment for each different
patient, thereby increasing overall treatment efficacy. In our opinion,
high-risk older patients and those with severe comorbidities should
undergo Botox, while all the other patients may be considered as low
risk and offered surgical or endoscopic treatment (Fig.2). The choice
between PD or surgery may depend on local expertise.
The role of POEM as a valuable substitute of the traditional
therapeutic options will be defined in the immediate future
after randomized prospective comparison trials and longterm follow-up studies are published. Pharmacological therapy
could be administered to patients waiting for an endoscopic
or surgical treatment and to those with high surgical risk
whenever the approach with Botox is not possible or has failed.
While current treatment of achalasia still focuses on mechanical
disruption of the LES, future therapies are anticipated aiming
at restoring its function.
High risk
Low risk
Type III
Type I-II
Heller Myotomy
PD 30 mm
Heller Myotomy
Relapse
Relapse
Relapse
Re-intervention
PD 35 mm
Botox
Botox
Relapse
Botox
Relapse
Relapse
PD 40 mm
Botox
Relapse
Annals of Gastroenterology 28
References
1. Boeckxstaens GE. The lower oesophageal sphincter.
Neurogastroenterol Motil 2005;17(Suppl1):13-21.
2. Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis
and management of achalasia. Am J Gastroenterol 2013;108:12381249; quiz 50.
3. Francis DL, Katzka DA. Achalasia: update on the disease and its
treatment. Gastroenterology 2010;139:369-374.
4. Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. Lancet
2014;383:83-93.
5. Vaezi MF, Baker ME, Achkar E, Richter JE. Timed barium
oesophagram: better predictor of long term success after
pneumatic dilation in achalasia than symptom assessment. Gut
2002;50:765-770.
6. Boeckxstaens GE, Annese V, des Varannes SB, et al. Pneumatic
dilation versus laparoscopic Hellers myotomy for idiopathic
achalasia. NEngl J Med 2011;364:1807-1816.
7. Gockel I, Junginger T. The value of scoring achalasia: a comparison
of current systems and the impact on treatment--the surgeons
viewpoint. Am Surg 2007;73:327-331.
8. Boeckxstaens GE. Achalasia: virus-induced euthanasia of neurons?
Am J Gastroenterol 2008;103:1610-1612.
9. Gockel I, Muller M, Schumacher J. Achalasia--a disease of
unknown cause that is often diagnosed too late. Dtsch Arztebl Int
2012;109:209-214.
10. De Giorgio R, Di Simone MP, Stanghellini V, et al. Esophageal and
gastric nitric oxide synthesizing innervation in primary achalasia.
Am J Gastroenterol 1999;94:2357-2362.
11. Park W, Vaezi MF. Etiology and pathogenesis of achalasia: the
current understanding. Am J Gastroenterol 2005;100:1404-1414.
12. Pandolfino JE, Fox MR, Bredenoord AJ, Kahrilas PJ. Highresolution manometry in clinical practice: utilizing pressure
topography to classify oesophageal motility abnormalities.
Neurogastroenterol Motil 2009;21:796-806.
13. Richter JE, Boeckxstaens GE. Management of achalasia: surgery or
pneumatic dilation. Gut 2011;60:869-876.
14. Bansal A, Kahrilas PJ. Has high-resolution manometry changed
the approach to esophageal motility disorders? Curr Opin
Gastroenterol 2010;26:344-351.
15. Lin Z, Kahrilas PJ, Roman S, Boris L, Carlson D, Pandolfino JE.
Refining the criterion for an abnormal Integrated Relaxation
Pressure in esophageal pressure topography based on the pattern
of esophageal contractility using a classification and regression tree
model. Neurogastroenterol Motil 2012;24:e356-e363.
16. Richter JE. Esophageal motility disorder achalasia. Curr Opin
Otolaryngol Head Neck Surg 2013;21:535-542.
17. Bortolotti M, Labo G. Clinical and manometric effects of
nifedipine in patients with esophageal achalasia. Gastroenterology
1981;80:39-44.
18. Wen ZH, Gardener E, Wang YP. Nitrates for achalasia. Cochrane
Database Syst Rev 2004:Cd002299.
19. Ghosh B, Das SK. Botulinum toxin: a dreaded toxin for use in
human being. JIndian Med Assoc 2002;100:607-608, 10-2, 14.
20. Ramzan Z, Nassri AB. The role of Botulinum toxin injection
in the management of achalasia. Curr Opin Gastroenterol
2013;29:468-473.
21. Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN.
Intrasphincteric botulinum toxin for the treatment of achalasia.
NEngl J Med 1995;332:774-778.
22. Annese V, Bassotti G, Coccia G, et al. Amulticentre randomised
study of intrasphincteric botulinum toxin in patients with
oesophageal achalasia. GISMAD Achalasia Study Group. Gut
2000;46:597-600.
23. Zaninotto G, Annese V, Costantini M, et al. Randomized controlled
308 F. Torresan et al
44. Katzka DA, Castell DO. Review article: an analysis of the efficacy,
perforation rates and methods used in pneumatic dilation for
achalasia. Aliment Pharmacol Ther 2011;34:832-839.
45. Vanuytsel T, Lerut T, Coosemans W, et al. Conservative
management of esophageal perforations during pneumatic dilation
for idiopathic esophageal achalasia. Clin Gastroenterol Hepatol
2012;10:142-149.
46. Metman EH, Lagasse JP, dAlteroche L, Picon L, Scotto B, Barbieux JP.
Risk factors for immediate complications after progressive pneumatic
dilation for achalasia. Am J Gastroenterol 1999;94:1179-1185.
47. OConnor JB, Singer ME, Imperiale TF, Vaezi MF, Richter JE. The
cost-effectiveness of treatment strategies for achalasia. Dig Dis Sci
2002;47:1516-1525.
48. Karanicolas PJ, Smith SE, Inculet RI, et al. The cost of laparoscopic
myotomy versus pneumatic dilatation for esophageal achalasia. Surg
Endosc 2007;21:1198-1206.
49. E. H. Extra mucous cardioplasty in chronic cardiospasm with
dilatation of the esophagus (Extramukose Cardiaplastik mit dilatation
des oesophagus). Mitt Grenzgels Med Chir 1913;27:141-148.
50. Zaaijer JH. Cardiospasm in the aged. Ann Surg 1923;77:615-617.
51. Dor J, Humbert P, Paoli JM, Miorclerc M, Aubert J. Treatment of
reflux by the so-called modified Heller-Nissen technic. Presse Med
1967;75:2563-2565.
52. Shimi S, Nathanson LK, Cuschieri A. Laparoscopic cardiomyotomy
for achalasia. JR Coll Surg Edinb 1991;36:152-154.
53. Ali A, Pellegrini CA. Laparoscopic myotomy: technique and
efficacy in treating achalasia. Gastrointest Endosc Clin N Am
2001;11:347-358, vii.
54. Richards WO, Torquati A, Holzman MD, et al. Heller myotomy
versus Heller myotomy with Dor fundoplication for achalasia:
a prospective randomized double-blind clinical trial. Ann Surg
2004;240:405-412; discussion 12-15.
55. Rebecchi F, Giaccone C, Farinella E, Campaci R, Morino M.
Randomized controlled trial of laparoscopic Heller myotomy plus
Dor fundoplication versus Nissen fundoplication for achalasia:
long-term results. Ann Surg 2008;248:1023-1030.
56. Rawlings A, Soper NJ, Oelschlager B, et al. Laparoscopic Dor versus
Toupet fundoplication following Heller myotomy for achalasia:
results of a multicenter, prospective, randomized-controlled trial.
Surg Endosc 2012;26:18-26.
57. Mattioli S, Ruffato A, Lugaresi M, Pilotti V, Aramini B, DOvidio F.
Long-term results of the Heller-Dor operation with intraoperative
manometry for the treatment of esophageal achalasia. J Thorac
Cardiovasc Surg 2010;140:962-969.
58. Costantini M, Zaninotto G, Guirroli E, et al. The laparoscopic
Heller-Dor operation remains an effective treatment for
esophageal achalasia at a minimum 6-year follow-up. Surg Endosc
2005;19:345-351.
59. Chen Z, Bessell JR, Chew A, Watson DI. Laparoscopic
cardiomyotomy for achalasia: clinical outcomes beyond 5 years.
JGastrointest Surg 2010;14:594-600.
60. Torquati A, Richards WO, Holzman MD, Sharp KW. Laparoscopic
myotomy for achalasia: predictors of successful outcome after
200cases. Ann Surg 2006;243:587-591; discussion 91-93.
61. Zaninotto G, Costantini M, Rizzetto C, et al. Four hundred
laparoscopic myotomies for esophageal achalasia: a single centre
experience. Ann Surg 2008;248:986-993.
62. Salvador R, Costantini M, Zaninotto G, et al. The preoperative
manometric pattern predicts the outcome of surgical treatment for
esophageal achalasia. JGastrointest Surg 2010;14:1635-1645.
Annals of Gastroenterology 28